LeMaitre Vascular, Inc.
HealthcareNASDAQ:LMAT · NASDAQ Global Market
-$0.38 today
Vol 0.21M · Avg 0.26M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$256.3M of revenue converted into $62.4M of net income for the selected period. Gross margin is 72.4% and net margin is 24.4%, showing how much revenue survives after costs and taxes. EPS is $2.71, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $249.6M +13.5% | $219.9M +13.6% | $193.5M +19.7% | $161.7M +4.7% | $154.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $71.1M +3.0% | $69.0M +3.8% | $66.4M +17.1% | $56.8M +7.0% | $53.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $178.5M +18.3% | $150.9M +18.8% | $127.0M +21.1% | $104.9M +3.5% | $101.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 71.5% +2.9pp | 68.6% +3.0pp | 65.7% +0.8pp | 64.9% -0.8pp | 65.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $14.1M -9.7% | $15.7M -7.8% | $17.0M +27.6% | $13.3M +12.7% | $11.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $96.5M +16.3% | $83.0M +13.9% | $72.9M +18.2% | $61.7M +16.0% | $53.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $110.6M +12.1% | $98.6M +9.2% | $90.3M +15.7% | $78.1M +20.2% | $65.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $10.4M +7.7% | $9.7M +1.6% | $9.5M +0.9% | $9.4M -0.4% | $9.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $90.8M +36.0% | $66.8M +36.3% | $49.0M +32.7% | $36.9M -19.7% | $46.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 36.4% +6.0pp | 30.4% +5.0pp | 25.3% +2.5pp | 22.8% -6.9pp | 29.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $67.9M +30.0% | $52.3M +42.3% | $36.7M +36.8% | $26.8M -26.3% | $36.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 27.2% +3.4pp | 23.8% +4.8pp | 19.0% +2.4pp | 16.6% -7.0pp | 23.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $13.1M +164.6% | $4.9M +60.8% | $3.1M +212.1% | $986.0K +400.5% | $197.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.2M +2428.8% | $205.0K | $0 | $0 -100.0% | $2.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $7.3M +57.4% | $4.6M +67.2% | $2.8M +318.0% | $661.0K +130.9% | -$2.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $75.2M +32.2% | $56.9M +44.1% | $39.5M +43.6% | $27.5M -19.8% | $34.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 30.1% +4.3pp | 25.9% +5.5pp | 20.4% +3.4pp | 17.0% -5.2pp | 22.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $17.4M +35.9% | $12.8M +37.0% | $9.4M +36.7% | $6.9M -7.1% | $7.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | $57.7M +31.1% | $44.0M +46.3% | $30.1M +45.9% | $20.6M -23.3% | $26.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | 23.1% +3.1pp | 20.0% +4.5pp | 15.6% +2.8pp | 12.8% -4.7pp | 17.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +30.1% | $2 +44.1% | $1 +44.7% | $1 -26.0% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +30.6% | $2 +44.0% | $1 +44.1% | $1 -25.6% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $22.6M +0.8% | $22.5M +1.1% | $22.2M +1.1% | $22.0M +3.9% | $21.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $22.9M +0.7% | $22.8M +1.6% | $22.4M +1.1% | $22.2M +3.2% | $21.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$4.74B
Haemonetics Corporation
NYSE:HAE
$3.55B
National HealthCare Corporation
AMEX:NHC
$3.09B
Acadia Healthcare Company, Inc.
NASDAQ:ACHC
$2.26B
Aveanna Healthcare Holdings Inc.
NASDAQ:AVAH
$1.54B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.46B
AtriCure, Inc.
NASDAQ:ATRC
$1.46B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Inspire Medical Systems, Inc.
NYSE:INSP
$1.23B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LMAT generate?
LeMaitre Vascular, Inc. (LMAT) reported $249.60M of revenue in fiscal 2025.
Is LMAT profitable?
LeMaitre Vascular, Inc. (LMAT) reported $57.73M of net income, with a net margin of 23.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.